Relay Therapeutics
The Head of Capital at Relay leads the company's equity fundraising efforts, managing the entire process from investor mapping and outreach to term sheet negotiation and closing. This role works closely with the CEO and CFO to build investor-facing materials, maintain financial models, and ensure a seamless fundraising process for current and future capital rounds. The position also involves maintaining investor relationships and preparing materials between funding rounds to support the company's rapid growth.
Headquarters
Cambridge, Massachusetts, United States
Company Size
51-200 employees
Founded
2016
Relay Therapeutics is a biotechnology company that puts protein motion at the heart of drug discovery, using computational modeling, machine learning, and experimental structural biology to reveal dynamic protein states and identify novel therapeutic opportunities. The company applies this platform to design and advance small‑molecule drug candidates, translating dynamic insights into lead programs and partnerships. Relay’s approach aims to expand the set of druggable targets and accelerate development of medicines across multiple disease areas.
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Analysts
18 hours ago
Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock?
1 day ago
Insider Sell: Thomas Catinazzo Sells Shares of Relay Therapeutics Inc (RLAY)
23 hours ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Relay Therapeutics.
Relay Therapeutics didn’t post a salary, so this is our estimate from similar listings.
Zovegalisib Milestones To Shape The Future Of Relay Therapeutics
1 day ago